Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
89Bio Inc
(NQ:
ETNB
)
8.040
-0.130 (-1.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 89Bio Inc
< Previous
1
2
3
4
5
6
7
Next >
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Appoints Francis Sarena as Chief Operating Officer
August 07, 2024
From
89bio, Inc.
Via
GlobeNewswire
ETNB Stock Earnings: 89bio Beats EPS for Q2 2024
August 05, 2024
ETNB stock results show that 89bio beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
August 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
ETNB Stock Earnings: 89bio Misses EPS for Q1 2024
May 09, 2024
ETNB stock results show that 89bio missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
August 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
June 05, 2024
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment....
Via
Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
June 05, 2024
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease.
Via
Investor's Business Daily
The Week Ahead: What's Next
June 02, 2024
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle.
Via
Talk Markets
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
May 22, 2024
-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-
From
89bio, Inc.
Via
GlobeNewswire
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
May 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
May 02, 2024
Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET
From
89bio, Inc.
Via
GlobeNewswire
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
April 17, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
March 27, 2024
From
89bio, Inc.
Via
GlobeNewswire
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
March 17, 2024
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Via
The Motley Fool
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
March 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
89bio, Inc.
Via
GlobeNewswire
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
March 07, 2024
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.
Via
Benzinga
89bio to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 04, 2024
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its...
Via
Benzinga
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
March 04, 2024
Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 04, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
March 04, 2024
We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
February 29, 2024
From
89bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.